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BACKGROUND AND PURPOSE
In non-obese diabetic animals, protease-activated receptor-2 (PAR2) agonists are more effective vasodilators, which is
attributed to increased COX-2 and endothelial NOS (eNOS) activities. Under conditions of diabetes and obesity, the
effectiveness of PAR2 agonists is unknown. We compared the vasodilator responses of small calibre mesenteric arteries from
obese diabetic B6.BKS(D)-Leprdb/J (db/db) induced by PAR2-activating agonists 2-furoyl-LIGRLO-amide (2ﬂy) and trypsin to
those obtained in controls [C57BL/6J (C57)], and assessed the contributions of COX, NOS and calcium-activated potassium
channels (KCa) to these responses.
EXPERIMENTAL APPROACH
Arteries mounted in wire myographs under isometric tension conditions were contracted submaximally by U46619 then
exposed to vasodilators. mRNA and protein expression of PAR2, eNOS and soluble GC (sGC) were determined by real-time
PCR and Western blots.
KEY RESULTS
ACh- and nitroprusside-induced relaxations were attenuated in db/db compared with C57. In contrast, 2ﬂy- and
trypsin-induced relaxations were largely retained in db/db. A NOS inhibitor partly inhibited ACh- and 2ﬂy-induced relaxations
in C57, but not those in db/db. Inhibitors of the COX-cAMP pathway (FR122044, SC560, NS398, SC58125, SQ22536,
CAY10441) did not affect these relaxation responses in either strain. Charybdotoxin (BKCa, SK3.1 blocker), but not iberiotoxin
(BKCa blocker), inhibited responses to the PAR2 agonists in db/db. In db/db protein levels of eNOS were higher, whereas those
of sGC were lower than in C57. PAR2 mRNA expression in db/db was higher than in C57.
CONCLUSIONS AND IMPLICATIONS
PAR2-mediated vasodilatation is protected against the negative effects of obesity and diabetes in mice. In diabetic vascular
dysfunction, preserved PAR2 vasodilatation was linked to activation of SK3.1.
Abbreviations
2ﬂy, 2-furoyl-LIGRLO-amide; BKCa, large (big) conductance KCa; ChTx, charybdotoxin; CRC, concentration–response
curve; eNOS, endothelial NOS; IbTx, iberiotoxin ; KCa, Ca2+-activated potassium channel; L-NAME, N
G-nitro-L-arginine
methyl ester; PAR2. protease-activated receptor 2; SK2.2/2.3, small-conductance KCa; SK3.1, intermediate-conductance
KCa; sGC, soluble GC
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The endothelium of blood vessels expresses protease-
activated receptor-2 (PAR2), one of four types of protease-
activated seven transmembrane G protein-coupled receptors
(Ramachandran and Hollenberg, 2008). Various identiﬁed
serine proteinases cleave a speciﬁc recognition site in the
extracellular N-terminus of PAR2 to unmask a hidden
sequence that then functions as a tethered ligand to activate
the receptor while other proteases disarm the receptor
(Hansen et al., 2008). PAR2 expression is found under normal
conditions on many epitheliums, nociceptive neuron termi-
nals, dorsal root ganglion bodies and glial cells. Thus, studies
have implicated a role for PAR2 in many disease conditions
including inﬂammation responses in cardiovascular, respira-
tory, gastrointestinal and nervous systems (Hansen et al.,
2008; Ramachandran and Hollenberg, 2008). With a few
exceptions, the consensus from the results of these studies is
that the role of PAR2 is to provide small inputs to modulate
disease and injury responses in experimental models. For
example, PAR2 gene deletion produces a haemodynamic phe-
notype characterized by modest (5%) elevation of systolic
blood pressures in conscious mice (McGuire et al., 2007).
Human diseases are complex phenotypes involving multiple
organ systems, thus the role of PAR2 still needs to be pursued
in many experimental models.
Humans with metabolic syndrome, which is a controver-
sial deﬁnition of health status characterized by the clustering
of multiple cardiovascular risk factors such as abdominal
obesity, insulin resistance and hypertension, are known to be
at higher risk of developing vascular diseases (Shaw et al.,
2005; Venkatapuram and Shannon, 2006). Increased PAR2
immunoreactivity has been reported in samples from human
coronary atherosclerotic lesions (Napoli et al., 2004) and in rat
carotid arteries after experimental angioplasty balloon-injury
(Damiano et al., 1999). Direct exposure to inﬂammatory sub-
stances, TNF-a and IL-1a, was reported to induce PAR2 expres-
sion in endothelium from human arteries in vitro (Hamilton
et al., 2001). However, the functional consequences, speciﬁ-
cally for PAR2-mediated endothelium-dependent responses,
such as vasodilatation, in these disease conditions are not
fully understood. In rodent models of hypertension, we and
others have reported that PAR2-mediated relaxation persists
in resistance arteries despite dysfunctional responses to other
endothelium-dependent agonists (Sobey and Cocks, 1998;
McGuire et al., 2007; Smeda and McGuire, 2007; Smeda et al.,
2010). In diabetes models, the sensitivity to PAR2-mediated
relaxation was increased in aortae from type 1 non-obese
diabetic (NOD) mice (Roviezzo et al., 2005) and in mesenteric
arteries from type 2 non-obese diabetic rats (Goto-Kakizaki)
(Matsumoto et al., 2009). In these models, PAR2-mediated
vasodilatation of large calibre arteries was dependent on the
up-regulation of either COX or NOS. However, the mecha-
nism of PAR2-mediated endothelium-dependent responses in
obese type 2 diabetes models is not known.
The main objective of this study was to investigate vas-
cular responses, especially those mediated by PAR2, in mesen-
teric arteries of obese type 2 diabetic B6.BKS(D)-Lepr
db/J mice
(db/db). A mutation of the leptin receptor in these mice
causes a lack of leptin receptor signalling in their hypothala-
mus, which leads to overeating, obesity, hyperglycaemia and
hyperlipidaemia in these mice, which is similar to human
type 2 diabetes and metabolic syndrome (Russell and Proctor,
2006; Kennedy et al. 2010). To date, db/db have been widely
used in studies that have evaluated diabetic complications,
including the dysfunction of vasodilatation mechanisms in
type 2 diabetes (Pannirselvam et al., 2002; Guo et al. 2005;
Belmadani et al. 2008; Miike et al., 2008; Park et al., 2008). In
this study, we found that the PAR2-mediated relaxations in
second order mesenteric arteries of obese type 2 diabetic
db/db were maintained while responses to ACh were attenu-
ated; this was attributed to altered protein levels of sGC and
eNOS. Neither COX-AC nor NO-sGC signalling appear to be
involved in these PAR2-mediated responses in db/db mice.
However, the mechanism of the preserved PAR2-mediated
vasodilatation was linked to calcium-activated potassium
channels (KCa), particularly SK3.1.
Methods
Animals
Male homozygous mice for the diabetes spontaneous muta-
tion in leptin receptor [B6.BKS(D)-Lepr
db/J (db/db; stock #697;
July 2009-October 2010)] and age-matched genetic back-
ground C57BL/6J (C57) (stock #664) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA). Mice
were fed a standard regular salt feed (NIH-31 autoclavable
open formula mouse diet; Zeigler Bros Inc., Gardners, PA,
USA) and provided water ad libitum while housed in the
Animal Care Facility. All protocols were approved by the
Institutional Animal Care Committee of Memorial University
in accordance with the guidelines and principles for use of
animals in research by the Canadian Council on Animal
Care. Mice (12 weeks of age), were anaesthetized with isoﬂu-
rane for cardiac puncture to obtain blood samples and then
killed by cervical dislocation.
Sources of drugs and reagents for
myograph studies
Unless stated otherwise, all drugs and reagents were obtained
from Sigma Aldrich (Oakville, Ontario, Canada). Other
sources included: Bachem (Torrance, CA, USA), charybdot-
oxin; Cayman Chemicals (Ann Arbor, MI, USA), CAY10441,
SC560, SC58125 and SQ22536; Peptides International (Lou-
isville, KT, USA), 2-furoyl-leu-ile-gly-arg-leu-orn-amide (2ﬂy);
Tocris BioScience (Ellisville, MO, USA): charybdotoxin
(ChTx), FR122047, NS398; and University of Calgary Peptide
Synthesis (Calgary, Alberta, Canada), 2-furoyl-orn-leu-arg-
gly-ile-leu-amide. Stock solutions of indomethacin,
FR122047, CAY10441, NS398, SC560, SC58125 and SQ22536
were made up in dimethylsulphoxide and added as a 1/1000
dilution to tissue bath solutions. Stock solutions of all other
drugs were made in water.
Vascular reactivity
Mesenteric arcades with attached adipose, blood vessels and
nerves were dissected free from gastrointestinal tract in situ
and immediately placed in ice-cooled Krebs buffered bicar-
bonate solution (114 mM NaCl, 4.7 mM KCl, 0.8 mM
KH2PO4, 1.2 mM MgCl2, 2.5 mM, CaCl2, 25 mM NaHCO3 and
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ies were cleaned of adherent tissue and cut into 1–2 mm
lengths. The arterial rings were positioned in small wire myo-
graph chambers (DMT 610M, DMT 620M) for the measure-
ment and recording of isometric tension (McGuire et al.,
2007). Each chamber contained Krebs buffered solution (pH
7.4) bubbled with 95% O2/5% CO2 at 37°C. Initial resting
tension for each artery was determined as described previ-
ously (McGuire et al., 2007), with initial effective pressure at
7.98 kPa. After an equilibration period (1 h), vascular reactiv-
ity was measured. Contractile responses were determined
from cumulative additions of potassium chloride (15–
120 mM), 9,11-dideoxy-9a,11a-methanoepoxy PGF2a
(U46619, 0.1 nM–3 mM) or phenylephrine (0.01–100 mM) to
the baths. To determine the relaxation response, the rings
were contracted by addition of small increments of U46619
to submaximal tensions [50–80% of Emax based on
concentration–response curves (CRC) data]. After a stable
contraction was obtained, a PAR2-activating peptide, 2ﬂy
(0.1 nM–3 mM), ACh (0.1 nM–100 mM) or nitroprusside
(0.1 nM–100 mM) was added cumulatively to the bath. The
contraction and relaxation responses were measured in either
the absence or presence of inhibitors (30 min), which
included N
G-nitro-L-arginine methyl ester (L-NAME, NOS
inhibitor, 100 mM), FR122047 (selective COX-1 inhibitor,
3 mM), SC560 (selective COX-1 inhibitor, 3 mM), NS398
(selective COX-2 inhibitor, 3 mM), SC58125 (selective COX-2
inhibitor, 10 mM), SQ22536 (AC inhibitor, 100 mM),
CAY10441 (PGI2 receptor antagonist, 0.3 mM), apamin
(SK2.2/2.3 inhibitor, 1 mM), ChTx (SK3.1/BKCa inhibitor,
50 nM) and iberiotoxin (BKCa inhibitor, 50 nM, IbTx). Inhibi-
tor treatment with these antagonists were reported as being
effective (Guo et al., 2005; Roviezzo et al. 2005; Cao et al.
2006; Yamada et al., 2008). In the experiments examining the
removal of endothelium, the negative control reversed
sequence PAR2-peptide (2-furoyl-OLRGIL-amide, 10 mM),
trypsin (15 U·mL
-1 = 30 nM; type IX-S porcine pancreas,
13 100 U·mg
-1) and the inhibition of KCa, rings were con-
tracted by U46619 as described above, then test compounds
including ACh (10 mM) and 2ﬂy (1 mM) were added at a single
maximal effective concentration. The exception was the
negative control peptide that was added at 10-times the
maximal effective concentration of 2ﬂy. Endothelium was
damaged by passing a human hair through the lumen of an
artery ring and was conﬁrmed by absence of relaxation to
ACh in the experiments.
Protein expression in whole
mesenteric arteries
Western blots were performed on mesenteric arteries homog-
enized in lysis buffer [1% NP-40, 10% glycerol, 1 mM NaF,
1m MN a 3VO4, 0.025% sodium dodecyl sulphate (SDS) and
protease inhibitors] using a glass homogenizer. Protein con-
centration was determined using a BCA protein assay kit
(Pierce Biotechnology, Inc., Rockford, IL, USA), then proteins
(5–20 mg) were loaded onto gels, separated by SDS polyacry-
lamide gel electrophoresis (8%) and transferred onto polyvi-
nylidine diﬂuoride membranes. Each sample was assayed in
duplicate at two protein levels. Membranes were incubated
separately with antibodies against COX-1 (Cayman Chemi-
cals), COX-2 (C-20, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), eNOS (BD Biosciences, Lexington, KY, USA),
sGC b1 subunit (Abcam, Inc., Cambridge, MA, USA) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (FL-
335, Santa Cruz Biotechnology). Immunoreactive bands on
membranes were recorded on X-ray ﬁlm by chemilumines-
cence detection according to supplier (SuperSignal West Pico
Thermo Fisher Scientiﬁc Inc., Rockford, IL, USA). Minor
modiﬁcations to the above procedures were made to assay
arterial protein with monoclonal anti-human PAR2 antibody
SAM11 (Molino et al., 1997; SC-13504, Santa Cruz Biotech-
nology) and can be found in Supporting Information. Target
band intensities were quantiﬁed by Image J (National Insti-
tute of Health, Bethesda, MD, USA). The density for GAPDH
bands from the same blots were used to normalize the target
band for quantitative analyses. Representative immunoblots
of experiments were repeated independently three times.
mRNA expression
mRNA expression was assayed using quantitative real-time
PCR methods. Mesenteric arterial beds were isolated as
described above then ﬂash frozen by immersion in liquid
nitrogen. Total RNA was extracted from frozen tissues and
then puriﬁed using an RNeasy ﬁbrous kit following manufac-
turer’s instructions (Qiagen, Mississauga, Ontario, Canada).
Real-time measurement of target gene expression was carried
out using TaqMan RNA-to-CT 1-step kit accordingly on an
ABI Prism 7000 light cycler (Applied Biosystems, Foster City,
CA, USA). The amount of RNA used was optimized for each
target gene primer-ﬂuorescent probe set. Gene speciﬁc
primer-probe sets were available commercially (Applied Bio-
systems, assay/product ID: PAR2, Mm00433160_m1; eNOS,
Mm00435204_m1; sGC, Mm00516926_m1; GAPDH,
4352932E; b2-microglobulin, Mm00437762_m1; calnexin,
Mm00500330_m1). Refer to Supporting Information Table S1
for more speciﬁc details on the TaqMan gene expression
assays selected. In some instances, to accommodate low indi-
vidual yield of samples, RNA was pooled from two to three
mice and each pooled set was treated as one independent
sample. Each sample was measured in duplicate. A triad
housekeeping gene expression approach (GAPDH,
b2-microglobulin, calnexin) was used for normalization of
sample material, and the efﬁciencies for primer sets for each
were included in all calculations.
Blood and urine levels of glucose and
serum insulin
Blood was collected by cardiac puncture on the date of myo-
graph experiments from each mouse while under isoﬂurane-
induced anaesthesia. The non-fasted blood and urine glucose
were determined using Elite glucometer (blood glucose test
strips 3986B, Bayer HealthCare LLC., Mishawaka, IN, USA)
and Chemistrips (10A, Roche Diagnostics, Quebec, Quebec,
Canada). Serum was separated by centrifugation at 3000¥ g
for 10 min at 4°C, and insulin levels were determined by
using ELISA (ultra sensitive mouse insulin ELISA, Crystal Chem.
Inc., Downers Grove, IL, USA).
Data analysis
For myograph studies, individual CRCs were analysed by
nonlinear regression curve ﬁtting of drug concentration-
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parameter logistic function. We compared the negative log
EC50 of the variables, Hill slope and Emax values between
groups by Student’s unpaired t test or two-way (strain ¥ artery
treatment) ANOVA as indicated in the legends of the Figures
and Tables. In myograph studies that involved single concen-
trations of test compounds, comparisons of relaxations were
determined by two-way or one-way ANOVA as indicated in the
legends of the ﬁgures. Statistics indicating signiﬁcant main
effects or interactions were followed by Bonferroni post hoc
for multiple comparison testing. P < 0.05 was considered
signiﬁcant. Myograph data are reported as mean  SE, and
n = number of mice. For protein expression data, target band
density in each lane was normalized to the corresponding
density for GAPDH. Protein, blood urine and serum data are
reported as mean  SE. Comparisons of variables between
strains were made by Student’s t-test for unpaired data. P <
0.05 was considered signiﬁcant. In quantitative real-time PCR
experiments, group-wise comparisons of relative expressions
and statistical analyses of the relative expression results from
real-time PCR were made using REST 2008 software (Pfafﬂ
et al., 2002) with data combined from three independent
experimental runs. Data are reported as mean and SE interval
for the ratio of db/db to C57 normalized target gene expres-
sion where n = number of independent samples. *P < 0.05 was
considered signiﬁcant.
Results
Metabolic phenotype of db/db mice
Body weights at 12 weeks of age of db/db (51.1  0.6 g; n =
20) were about twofold heavier than age-matched control
C57 (27.5  0.5 g; n = 20; P < 0.05). Blood glucose levels of
db/db were two times higher (22.9  1.9 mmol·L
-1; n = 10)
than C57 (11.1  1.3 mmol·L
-1; n = 10; P < 0.05). Serum
insulin levels of db/db were 30 times higher (34.1 
5.5 ng·mL
-1; n = 10) than C57 (1.13  0.14 ng·mL
-1; n = 10;
P < 0.05). Glucose was elevated (>55 mmol·L
-1) in urine from
db/db, whereas in C57, it was at minimum detectable levels
(<2 mmol·L
-1).
Vasoreactivity of second order mesenteric
arteries from db/db mice
Contractions of mesenteric arteries induced by exposure to
high K
+, U46619 and phenylephrine were not different
between db/db and C57 (Figure 1).
Relaxations induced by the PAR2-activating peptide 2ﬂy
were preserved in db/db (Figure 2A, Table 1). On the other
hand, ACh-induced relaxations of mesenteric arteries from
db/db were attenuated compared with C57 (Figure 2B,
Table 1). Damaging the endothelium of the arteries abolished
the relaxations induced by both agonists in both strains [P >
0.05, relaxation values were not different from 0, one sample
t-test, C57 (n = 3 to 5); db/db (n = 6 to 7)]. A control peptide
consisting of the reversed active amino acid sequence,
2-furoyl-OLRGIL-amide (10 mM), had no effect on either C57
(n = 6) or db/db (n = 6) arteries contracted by U46619 (P >
0.05, relaxation values were not different from 0, one sample
t-test).
Changes in NO-mediated relaxations in
mesenteric arteries from db/db mice
To test the sensitivity of vascular smooth muscle cells to NO,
nitroprusside (a NO donor)-induced relaxations were deter-
mined. The concentration–relaxation curve was signiﬁcantly
shifted to the right in db/db mice (P < 0.05, –logEC50 C57 vs
db/db), but maximum responses were not signiﬁcantly dif-
ferent between the two strains (Figure 2C and Table 1).
To test the contribution of eNOS activity to 2ﬂy- and
ACh-induced relaxations of U46619-contracted db/db
mesenteric arteries, we obtained relaxation responses in the
presence of an NOS inhibitor, L-NAME. L-NAME partly inhib-
ited both the 2ﬂy- and ACh-induced relaxations in C57 mice
Figure 1
Extracellular K
+, U46619 and phenylephrine concentration-contraction response curves in db/db and C57BL/6J mesenteric arteries. Values are the
mean  SE (n = number of mice) for isometric tension changes to resting (untreated) baseline of isolated second order mesenteric arteries (2 mm
lengths) after exposure to (A) various high K
+ solutions (isoosmotic balanced with Na
+), cumulative concentrations of (B) U46619 and (C)
phenylephrine. There were no signiﬁcant effects of strain on the responses to the drugs (P > 0.05, Student’s t-test for unpaired data).
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of these responses in db/db mice (Figure 3B and D). In con-
trast, nitroprusside-induced relaxations were not inhibited by
L-NAME in either strain of mice (Figure 3E and F).
To determine whether changes in the eNOS–sGC axis
contributed to the lower sensitivity to NO, we assessed their
protein expression in mesenteric arterial bed using the
Western blot technique. Protein expression of eNOS was
higher in db/db than in C57 mice, and sGC was lower in
db/db than in the C57 strain (Figure 4).
Involvement of the COX pathway in
PAR2-mediated relaxations in db/db mice
We determined the effects of selective COX-1 and COX-2
inhibitors on PAR2-mediated relaxations of mesenteric arter-
ies to investigate the involvement of this pathway in the
responses. COX-1-selective inhibitors, FR122047 and SC560,
did not affect PAR2-mediated relaxations in either db/db or
C57 mice (Figure 5A–D). Similar results were obtained for
the COX-2 inhibitors, NS398 and SC58125 (Figure 5E–H).
Furthermore, in agreement with the results obtained with
the COX inhibitors, neither an AC inhibitor, SQ22536 nor a
PGI2 antagonist, CAY10441, inhibited the PAR2-mediated
responses in either strain (Figure 6A–D). In addition, the
protein expressions of COX-2 and COX-1 in the mesenteric
arteries of db/db were not signiﬁcantly different from those in
the C57 mice (data not shown).
Contribution of KCa to PAR2-mediated
relaxations in db/db mice
We determined the effects of BKCa, SK3.1, SK2.2 and SK2.3
inhibitors on PAR2-mediated relaxations of mesenteric arter-
ies in db/db mice to investigate the contributions of KCa to
these responses (Figure 7). In the presence of L-NAME, a com-
bination of apamin (SK2.2 and SK2.3 inhibitor) plus ChTx
(BKCa and SK3.1 inhibitor) abolished the ACh- and 2ﬂy-
induced relaxations in both C57 and db/db arteries
(Figure 7A and B). To broaden the scope of our study of PAR2
agonists in db/db, we tested enzyme-mediated PAR2 activity.
We compared low-dose trypsin (15 U·mL
-1)-induced relax-
ations of mesenteric arteries in C57 and db/db (Figure 7C).
Trypsin-induced relaxations of untreated C57 were not sig-
niﬁcantly different from those in untreated db/db (Bonfer-
roni post hoc). In the presence of L-NAME, apamin plus ChTx
abolished the trypsin-induced relaxations of mesenteric arter-
ies in both C57 and db/db mice (Figure 7C).
To differentiate between the contributions of BKCa and
SK3.1 to the response, we determined the effects of IbTX and
ChTx on ACh-, 2ﬂy- and trypsin-induced relaxations of
db/db arteries. ChTx (BKCa and SK3.1 inhibitor) abolished
the residual non-NO-mediated ACh-mediated relaxations
(Figure 8A). The BKCa-selective inhibitor IbTx inhibited ACh-
induced relaxations as effectively as ChTx in db/db. In con-
trast, the attenuation of the 2ﬂy- and trypsin-induced
relaxations induced by ChTx was not reproduced by substi-
tuting IbTx for ChTx (Figure 8B and C). Trypsin-induced
vasodilation was abolished by damaging the endothelium in
C57 (n = 3) and db/db (n = 7; P > 0.05, relaxation values were
not different than 0, one sample t-test).
Changes in PAR2 expressions in mesenteric
artery of db/db mice
PAR2 mRNA expression (normalized to triad housekeeper)
was signiﬁcantly up-regulated in db/db mesenteric arterial
Figure 2
2-furoyl-LIGRLO-amide (2ﬂy), ACh and nitroprusside concentration-
relaxation response relationships of db/db and C57BL/6J (C57)
mesenteric arteries. Values are the mean  SE (n = number of mice)
for (A) 2ﬂy- (B) ACh- and (C) nitroprusside-induced relaxations of
db/db and C57 second order mesenteric arteries contracted sub-
maximally by U46619. 100% relaxation = complete reversal of con-
tractions. *P < 0.05, db/db compared with C57 in (B) –logEC50 and
Emax and (C) –logEC50, Student’s t-test for unpaired data.
BJP
S Kagota et al.
362 British Journal of Pharmacology (2011) 164 358–371beds (Table 3). On the other hand, mRNA expressions of
eNOS and sGC were not signiﬁcantly different between the
two strains (Table 3). Western blots of arterial protein from
C57 and db/db assayed with anti-human PAR2 monoclonal
antibody (SAM11) (Molino et al., 1997) detected an immu-
noreactive band with a relative molecular weight correspond-
ing to a positive control for PAR2 in mouse cell line (NIH 3T3)
lysate (Figure S1A). The densities of the SAM11-reactive
bands (normalized to GAPDH) in C57 were not different from
those in db/db (Supporting Information Figure S1B). Further
test of the speciﬁcity of SAM11 antibody indicated the pres-
ence of equivalent immunoreactive bands in arterial protein
from PAR2 knockout mice (Supporting Information
Figure S1C).
Discussion
The main ﬁndings of the present study are that PAR2-
mediated vascular smooth muscle relaxations were preserved
in small mesenteric arteries of obese type 2 diabetic db/db,
even though endothelial NO release and NO responsiveness
of vascular smooth muscle were reduced. These ﬁndings are
novel in that the mechanism underlying the PAR2 resistance
Table 1
Parameters for 2-furoyl-LIGRLO-amide (2ﬂy), ACh and nitroprusside concentration-relaxation response curves in db/db and C57 mesenteric
arteries
Drugs Strain -log EC50 Hill slope Emax (%)
2ﬂy C57 8.22  0.12 2.4  0.6 96  1
db/db 8.03  0.08 2.1  0.3 97  1
ACh C57 7.23  0.09 1.2  0.1 92  1
db/db 6.49  0.15
a 1.1  0.2 72  4
a
Nitroprusside C57 8.08  0.17 1.0  0.1 93  1
db/db 7.20  0.12
a 1.1  0.2 93  1
Values are mean  SE for n = 15 mice per strain.
Variables were determined by curve ﬁtting data points from cumulative drug concentration–response relationships to four parameter logistic
equation.
aP < 0.05, db/db compared with C57BL/6J (C57), Student’s t-test for unpaired data.
Emax, maximum relaxation response (%) where 100% is the complete reversal of contraction.
Table 2
Effects of L-NAME on 2ﬂy, ACh and nitroprusside concentration-relaxation response curves in db/db and C57BL/6J (C57) mesenteric arteries
Drugs Strain (n) Treatment –logEC50 (M) Hill slope Emax (%)
2ﬂy C57 (9) Control 8.26  0.12 2.0  0.3 96  1
C57 (9) L-NAME 7.94  0.10
a 1.3  0.2
a 90  4
db/db (9) Control 8.07  0.09 2.3  0.3 98  1
db/db (9) L-NAME 7.95  0.11 2.2  0.3 92  3
ACh C57 (6) Control 7.13  0.10 1.2  0.2 93  2
C57 (6) L-NAME 6.97  0.18 1.6  0.3 52  9a
db/db (6) Control 6.57  0.18 1.0  0.2 67  6
db/db (6) L-NAME 6.57  0.43 1.4  0.3 56  12
Nitroprusside C57 (6) Control 7.86  0.33 0.9  0.1 93  2
C57 (6) L-NAME 7.69  0.16 1.3  0.4 95  5
db/db (6) Control 7.27  0.14 1.3  0.4 90  3
db/db (6) L-NAME 7.05  0.24 1.0  0.2 91  6
Values represent mean  SE for n = number of mice.
Variables were determined by curve ﬁtting data points from cumulative drug concentration–response relationships to four parameter logistic
equation.
aP < 0.05, L-NAME compared with control within strain, two-way ANOVA (strain ¥ artery treatment) followed by Bonferroni post hoc test.
Emax, maximum relaxation response where 100% is complete reversal of contraction. L-NAME (100 mM, 20 min).
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changes in either the COX or NO pathways, which have been
reported in non-obese type 1 diabetic mice and non-obese
type 2 diabetic rats. In db/db, the CRC to the PAR2-activating
peptide was not signiﬁcantly different from that in C57 mice
(Figure 2), indicating equivalent efﬁcacy for vasodilatation by
PAR2 mechanisms. We found that the PAR2-mediated vasodi-
latation induced by a PAR2-activating peptide and a selective
Figure 3
Effects of pretreatment of mesenteric arteries with an inhibitor of NOS on 2-furoyl-LIGRLO-amide (2ﬂy)-, ACh- and nitroprusside-induced
relaxations in db/db and C57BL/6J (C57) mice. Values are the mean  SE (n = number of mice) for (A, B) 2ﬂy- (C, D) ACh-, and nitroprusside (E,
F) induced relaxations of C57 and db/db second order mesenteric arteries contracted submaximally by U46619 in the absence or presence of
pretreatment with L-NAME (100 mM, 20 min). *P < 0.05, C57 untreated (control) compared with L-NAME in (A) –logEC50 and hill slope (C) Emax,
2-way ANOVA and Bonferroni post hoc test.
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endothelium-dependent. If the PAR2-mediated response
depends on the same signalling pathways as the endothelial
cell-dependent agonist ACh, then the PAR2-mediated actions
should have been reduced in db/db mice. An increase in the
level of PAR2 mRNA was observed in the mesenteric arteries
of db/db compared to C57 mice, which strongly suggests that
PAR2 receptor expression was not reduced by obese type 2
diabetes caused by the leptin receptor mutation in db/db. In
non-obese diabetic mice (type 1) and type 2 diabetic rats,
enhanced PAR2-mediated relaxations and increased mRNA
and protein expression in the vascular smooth muscle and
endothelium have been reported in large calibre aortas and
superior mesenteric arteries, respectively (Roviezzo et al.,
2005; Matsumoto et al. 2009). Our data together with results
obtained from studies in other diabetic models suggest that
PAR2-mediated vasodilatations of small- and large-calibre
arteries are universally retained independently of the cause or
type of diabetes, which differ signiﬁcantly among the differ-
ent animal models.
It has been reported that even very brief periods of hyper-
glycaemia inhibit endothelium-dependent vasodilator activ-
ity (Cosentino and Luscher, 1998; Honing et al., 1998);
notably, such responses depend on the production and bio-
availability of NO. PAR2 activation causes vasodilatation via
the production of NO in large-calibre arteries (aortas, femoral
arteries) from normal mice (McGuire et al., 2002a). In non-
obese type 2 diabetes, increased production of NO from
endothelium has been reported as the mechanism underlying
the enhanced PAR2-mediated relaxations of superior mesen-
teric arteries of Goto-Kakizaki rats (Matsumoto et al., 2009).
In contrast, it has been shown that decreased bioavailability
of NO is involved in the inhibition of endothelium-
dependent relaxations to ACh in the small-calibre mesenteric
arteries of db/db (Pannirselvam et al., 2002). Therefore, we
investigated the possibility that NO contributes to the pres-
ervation of PAR2-mediated relaxations in db/db. Indeed,
endothelial NO release and NO responsiveness were reduced
in db/db small mesenteric arteries. Firstly, we found that the
CRC to 2ﬂy was rightward shifted by L-NAME in C57 arteries,
but the CRCs were not signiﬁcantly different between con-
trols and L-NAME treated arteries in db/db. Secondly, we
found that the CRCs to nitroprusside were rightward shifted
in db/db arteries compared with C57 arteries. An attenuated
sensitivity of vascular smooth muscle to nitroprusside has
been reported in aortas of db/db (Miike et al., 2008) and
ob/ob mice (a model of obesity and type 2 diabetes) (Okon
et al., 2003), in aorta and mesenteric artery of rats with obese
and type 2 diabetes (Kagota et al., 2006; 2010), and in diabetic
patients (Levy et al., 1994). Thirdly, we found that protein
expression of eNOS was higher in db/db than in C57, while
sGC expression was less in db/db than in C57. These ﬁndings
Figure 4
Expression of eNOS and sGC in db/db and C57BL/6J (C57) mesenteric arteries. Upper panels show representative data collected from two db/db
and two C57 mice indicating immunoreactive bands corresponding to eNOS and sGC b1 subunit. Each sample was assayed in duplicate at
different protein amounts. Lower panels summarize densitometry data collected from four db/db and four C57 mice for eNOS and sGC. Target
bands were normalized to the densities of GAPDH bands. *P < 0.05, db/db compared with control, Student’s t-test for unpaired data.
Table 3
mRNA expression of protease-activated receptor 2, endothelial NOS
and soluble GC in db/db and C57BL/6J (C57)
mRNA
Ratio
(db/db to C57) SE range
PAR2 1.66
a 1.09–2.31
eNOS 1.35 0.67–3.18
sGC b1-subunit 1.16 0.71–1.75
mRNA expression in mesenteric arterial cascades was deter-
mined by real-time PCR and normalized to a triad housekeeping
genes.
db/db, n = 9 to 10; C57, n = 5t o6 .
SE range: mean minus lower SE to mean plus upper SE.
aP < 0.05, db/db compared with C57. See Methods for details of
statistical analyses.
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were preserved even though NO-mediated relaxations were
reduced in db/db mesenteric arteries. The simplest interpre-
tation for the deterioration of NO responses would be to
attribute it to the lower sGC levels in mesenteric vasculature.
However, one possible explanation for the increase in eNOS
protein was the presence of more monomeric eNOS in db/db
than C57 blood vessels. It has been proposed that monomeric
Figure 5
Effects of selective inhibitors of COX-1 (FR122047 and SC560) and -2 (NS398 and SC58125) on 2-furoyl-LIGRLO-amide (2ﬂy)-induced relaxations
of db/db and C57BL/6J (C57) mesenteric arteries. Values are the mean  SE (n = number of mice) for 2ﬂy-induced relaxations of C57 and db/db
second order mesenteric arteries contracted submaximally by U46619 in the absence or presence of (A, B) FR122047 (3 mM) (C, D) SC560 (3 mM)
(E, F) NS398 (3 mM) and (G, H) SC58125 (10 mM), respectively. Arteries were exposed to inhibitors for 30 min prior to U46619. There were no
signiﬁcant effects of inhibitors or strain on relaxation responses (P > 0.05, 2-way ANOVA).
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by causing an uncoupling of the production of reactive
oxygen species. Nevertheless, in db/db, the NO pathway was
not functioning the same as in C57, thus this mechanism
is unlikely to underlie the preserved PAR2-mediated
relaxations.
COX regulates vascular tone via the production of pros-
taglandins, and an up-regulation of mRNA/protein expres-
sion of COX, particularly COX-2, in vascular walls has been
shown in experimental models and in humans with diabetes
(Guo et al., 2005; Roviezzo et al., 2005; Szeraﬁn et al. 2006;
Nacci et al. 2009). However, there is still controversy regard-
ing the signiﬁcance of their role in the dysfunctional vascular
response occurring in diabetes. For example, increased
expression of COX in aortic smooth muscle contributes to
enhanced contractions to 5-HT, angiotensin II, phenyleph-
rine and high potassium in db/db type 2 diabetic mice (Guo
et al., 2005). However, we found that the contractions to high
potassium, U46619 and phenylephrine were unchanged in
db/db mesenteric arteries. On the other hand, streptozotocin-
induced type 1 diabetic mice show an increased endothelial
COX-2 expression, and this up-regulation is a compensatory
response that opposes the endothelial dysfunction (Nacci
et al., 2009). Furthermore, increased COX-2 expression in
aortic smooth muscle has been associated with the mecha-
nism underlying enhanced PAR2-mediated relaxations in
NOD mice (Roviezzo et al., 2005). Therefore, to test the con-
tribution of COX pathway in preserving PAR2-mediated
relaxations in db/db, we determined the protein expressions
of COX-1 and COX-2, and the effects of their selective inhibi-
tors on PAR2-mediated relaxations of mesenteric arteries.
Contrary to the ﬁndings in other diabetic animals, neither
COX-1 nor COX-2 expression were signiﬁcantly different
between db/db and C57, and the CRCs to 2ﬂy were not
signiﬁcantly different in the presence or absence of the selec-
tive COX-1, COX-2, AC inhibitors and PGI2 receptor antago-
nist in db/db. Thus, we conclude that the mechanism
underlying PAR2 resistance to diabetic vascular dysfunction is
not linked to the COX-cAMP pathway in db/db.
In various resistance arteries, which include middle cere-
bral and second order mesenteric arteries, PAR2 mediates
vasodilatation by inducing a non-NO non-COX-mediated
endothelium-dependent hyperpolarization (EDH) of vascular
smooth muscle (McGuire et al., 2002b; 2004; Smeda and
McGuire, 2007; Smeda et al. 2010). Evidence of some com-
pensatory increases in such non-NO mechanisms has been
obtained in mesenteric and coronary arteries of db/db (Pan-
nirselvam et al., 2002; 2006; Park et al., 2008). Of particular
importance to our study are the observations that IbTx or
ChTx alone were able to block ACh-induced EDH relaxations
of db/db mesenteric arteries (Pannirselvam et al., 2006). We
reproduced those ﬁndings (Figure 8A) and tested the
Figure 6
Effects of an AC inhibitor (SQ22536) and PGI2 receptor antagonist (CAY10441) on 2-furoyl-LIGRLO-amide (2ﬂy)-induced relaxations of db/db and
C57BL/6J (C57) mesenteric arteries. Values are the mean  SE (n = number of mice) for 2ﬂy-induced relaxations of C57 and db/db second order
mesenteric arteries contracted submaximally by U46619 in the absence or presence of (A, B) SQ22536 (100 mM) (C, D) CAY10441 (0.3 mM).
Arteries were exposed to inhibitors for 30 min prior to U46619. There were no signiﬁcant effects of inhibitors or strain on relaxation responses
(P > 0.05, 2-way ANOVA).
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Effects of KCa inhibition by apamin + charybdotoxin on ACh, 2-furoyl-
LIGRLO-amide (2ﬂy)- and trypsin-induced relaxations of db/db and
C57BL/6J (C57) mesenteric arteries. Columns are the mean  SE
(n = number of mice) for (A) ACh- (B) 2ﬂy- and (C) trypsin-induced
relaxations of C57 and db/db second order mesenteric arteries con-
tracted submaximally by U46619. Arteries were exposed to inhibitors
[100 mM L-NAME, 1 mM apamin, 50 nM charybdotoxin (ChTx)]
for 30 min prior to U46619. *P < 0.05, compared with C57
control (untreated); **P < 0.05, compared with same strain control
(untreated); ***P < 0.05, compared with same strain control
(untreated) and same strain L-NAME-treated, two-way ANOVA (strain
¥ treatment) and Bonferroni post hoc. a P < 0.05, main effect of strain
contributed 2.5% of total variation, two-way ANOVA. In (C) control
C57 vs. control db/db, and control db/db vs. L-NAME-treated db/db
were not different, Bonferroni post hoc. In (B) and (C), the interaction
between strain and treatment was not signiﬁcant (P > 0.05).
Figure 8
Effects of iberiotoxin (IbTx) and charybdotoxin (ChTx) on ACh,
2-furoyl-LIGRLO-amide (2ﬂy)- and trypsin-induced relaxations of
db/db mesenteric arteries. Columns are the mean  SE (n = number
of mice) for (A) ACh- (B) 2ﬂy- and (C) trypsin-induced relaxations of
db/db second order mesenteric arteries contracted submaximally by
U46619. Arteries were exposed to inhibitors (100 mM L-NAME,
50 nM IbTx, 50 nM ChTx) for 30 min prior to U46619. *P < 0.05,
compared with control (untreated) 1 way ANOVA and Bonferroni post
hoc.
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8). Based on the inhibition by ChTx, but not by IbTx, we
conclude that both the enzyme- and PAR2-activating peptide-
mediated relaxations are produced primarily via activation of
SK3.1 in db/db (Figure 8B and C). The PAR2-mediated relax-
ations induced by 2ﬂy and trypsin were endothelium-
dependent in db/db. Thus, an endothelium-derived
hyperpolarizing response via SK3.1 contributes to the reten-
tion of the PAR2-mediated relaxation in mesenteric artery of
db/db.
An additional explanation for the preservation of the
2ﬂy-induced relaxation is that PAR2 expression is changed in
db/db. We found a higher level of PAR2 mRNA in mesenteric
arteries of db/db, but we did not ﬁnd any differences in
PAR2 protein expression. However, our data show that the
monoclonal antibody SAM11, which was raised against the
tethered ligand of human PAR2 (Molino et al., 1997), is cross-
reactive with an unknown target in arterial protein isolated
from PAR2-knockout mice. This creates uncertainty about the
application of this antibody in Western blots to measure
PAR2 protein in rodent vascular tissue (Aman et al., 2010).
Although the relaxation activity of PAR2 was found to be
endothelium-dependent in mesenteric arteries of db/db, this
does not exclude the possibility of changes in vascular
smooth muscle PAR2 expression occurring in these mice.
Where and how PAR2 is expressed in mesenteric arteries of
db/db remains unknown. An up-regulation of PAR2 expres-
sion by pro-inﬂammatory cytokines and agents, for example
IL-1b, TNF-a and LPS, has been demonstrated in both in vitro
and in vivo studies (Cicala et al. 1999; Hamilton et al., 2001).
Chronic low-grade inﬂammation may be a condition linking
the occurrence of excessive amounts of adipose tissue to
obesity-associated pathologies such as type 2 diabetes and
cardiovascular diseases. Adipose tissue produces leptin, angio-
tensinogen, TNF-a, IL-6 and monocyte chemoattractant
protein-1, which all have the ability to contribute to vascular
inﬂammation (Dandona et al. 2005; Paoletti et al., 2006;
Zhang and Zhang, 2009; Ikeoka et al. 2010). These observa-
tions lead to a novel hypothesis that the inﬂammatory adi-
pokines contribute to the up-regulation of PAR2 in arteries of
db/db mice. Further studies are needed to deﬁne the mecha-
nisms and the pathophysiological signiﬁcance of the PAR2
gene regulation changes in db/db.
In conclusion, PAR2-mediated relaxations were protected
from vascular dysfunction in db/db. SK3.1 activation was the
primary mechanism for the PAR2-mediated vasodilatation in
db/db. Our ﬁndings indicate that the COX and/or NO
pathway do not contribute to the PAR2-mediated relaxations
in obese type 2 diabetic db/db. Preserved vascular PAR2 activ-
ity and increased expression may be linked to cardiovascular
inﬂammation caused by obesity under conditions of type 2
diabetes.
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–/–)
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molecular weight ladders; values (kDa) of the relative
molecular weight standards are included in (C). Target bands
were normalized to the densities of GAPDH bands. P > 0.05,
db/db compared with control Student’s t-test for unpaired
data.
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